Findings of Research Misconduct, 60694-60695 [2023-19086]
Download as PDF
<![CDATA[
60694
Federal Register / Vol. 88, No. 170 / Tuesday, September 5, 2023 / Notices
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
respondents
Form name
Institution/Loan Repayment Employment Form ..................
Authorization to Release Information Form .........................
Disadvantaged Background Form .......................................
* 215
215
215
Total ..............................................................................
860
Number of
responses
per
respondent
Average
burden per
response
(in hours)
Total
responses
1
1
1
215
215
215
Total
burden
hours
1.00
.25
.20
215.00
53.75
43.00
526.75
* Respondents for this form is the institution on behalf of the applicant.
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2023–19054 Filed 9–1–23; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the National Vaccine
Advisory Committee
Office of Infectious Disease and
HIV/AIDS Policy, Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) hereby gives notice that
the National Vaccine Advisory
Committee (NVAC) will hold an inperson meeting. The meeting will be
open to the public and public comment
will be heard during the meeting.
DATES: The meeting will be held
September 21–22, 2023. The confirmed
meeting times and agenda will be
posted on the NVAC website at https://
www.hhs.gov/nvpo/nvac/meetings/
index.html as soon as they become
available.
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
Instructions regarding
attending this meeting will be posted
online at: https://www.hhs.gov/nvpo/
nvac/meetings/ at least one
week prior to the meeting. Preregistration is required for those who
wish to attend the meeting in person or
ADDRESSES:
VerDate Sep<11>2014
18:02 Sep 01, 2023
Jkt 259001
participate in public comment. Please
register at https://www.hhs.gov/nvpo/
nvac/meetings/.
FOR FURTHER INFORMATION CONTACT: Ann
Aikin, Acting Designated Federal
Officer, Office of Infectious Disease and
HIV/AIDS Policy, U.S. Department of
Health and Human Services, Tower
Building, Room, 1101 Wootton
Parkway, Rockville, MD 20852. Email:
nvac@hhs.gov. Phone: 202–795–7697.
SUPPLEMENTARY INFORMATION: Pursuant
to section 2101 of the Public Health
Service Act (42 U.S.C. 300aa–1), the
Secretary of HHS was mandated to
establish the National Vaccine Program
to achieve optimal prevention of human
infectious diseases through
immunization and to achieve optimal
prevention against adverse reactions to
vaccines. The NVAC was established to
provide advice and make
recommendations to the Director of the
National Vaccine Program on matters
related to the Program’s responsibilities.
The Assistant Secretary for Health
serves as Director of the National
Vaccine Program.
During this meeting, NVAC will hear
presentations to support the recent
charges on innovation and safety from
Admiral Rachel L. Levine, MD, the
Assistant Secretary for Health and
Director of the National Vaccine
Program. NVAC will also hear
presentations on the actions and
strategies taken to better address the
unique vaccination needs of people
with disabilities, respiratory disease
prevention plans for the upcoming fall
season, and updates on climate change
vaccines. Please note that agenda items
are subject to change, as priorities
dictate. Information on the final meeting
agenda will be posted prior to the
meeting on the NVAC website: https://
www.hhs.gov/nvpo/nvac/.
Members of the public will have the
opportunity to provide comment at the
NVAC meeting during the public
comment period designated on the
agenda. Public comments made during
the meeting will be limited to three
minutes per person to ensure time is
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
allotted for all those wishing to speak.
Members of the public may also submit
written comments. Written comments
should not exceed three pages in length.
Individuals planning to submit
comments should email their written
comments or their request to provide a
comment during the meeting to nvac@
hhs.gov at least five business days prior
to the meeting.
Dated: August 7, 2023.
Ann Aikin,
Acting Designated Federal Official, Office of
the Assistant Secretary for Health.
[FR Doc. 2023–18994 Filed 9–1–23; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY:
ACTION:
Office of the Secretary, HHS.
Notice.
Findings of research
misconduct have been made against
Ivana Frech, Ph.D. (formerly Ivana De
Domenico) (Respondent), former
Assistant Professor, Department of
Internal Medicine, University of Utah
(UU) School of Medicine. Respondent
engaged in research misconduct in
research supported by U.S. Public
Health Service (PHS) funds, specifically
National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK),
National Institutes of Health (NIH),
grants R01 DK070947, R01 DK090257,
and R01 DK030534, National Institute of
General Medical Sciences (NIGMS),
NIH, grant P50 GM082545, National
Institute of Allergy and Infectious
Diseases (NIAID), NIH, grant R01
AI051174, and National Heart, Lung,
and Blood Institute (NHLBI), NIH, grant
R01 HL026922. The administrative
actions, including debarment for a
period of three (3) years, were
implemented beginning on August 21,
2023, and are detailed below.
SUMMARY:
E:\FR\FM\05SEN1.SGM
05SEN1
Federal Register / Vol. 88, No. 170 / Tuesday, September 5, 2023 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
Sheila Garrity, JD, MPH, MBA, Director,
Office of Research Integrity, 1101
Wootton Parkway, Suite 240, Rockville,
MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Ivana Frech, Ph.D. (formerly Ivana De
Domenico), University of Utah: Based
on the evidence and findings of an
investigation conducted by UU, ORI’s
oversight review of UU’s investigation,
and additional analysis conducted by
ORI during its oversight review, ORI
found that Ivana Frech, Ph.D. (formerly
Ivana De Domenico), former Assistant
Professor, Department of Internal
Medicine, UU School of Medicine,
engaged in research misconduct under
42 CFR part 93 in research supported by
PHS funds, specifically NIDDK, NIH,
grants R01 DK070947, R01 DK090257,
and R01 DK030534, NIGMS, NIH, grant
P50 GM082545, NIAID, NIH, grant R01
AI051174, and NHLBI, NIH, grant R01
HL026922.
ORI found by a preponderance of the
evidence that Respondent intentionally,
knowingly, or recklessly falsified and/or
fabricated western blot and
autoradiogram images related to
mechanisms of cellular iron regulation
by reusing, relabeling, and manipulating
images to falsely report data in eight (8)
figures included in the following three
(3) PHS-supported published papers:
• Two Distinct Modes of ESCRT–III
Recognition are Required for VPS4
Functions in Lysosomal Protein
Targeting and HIV–1 Budding. Dev Cell.
2008 Jul;15(1):62–73. doi: 10.1016/
j.devcel.2008.05.014 (hereafter referred
to as ‘‘Dev. Cell 2008’’).
• The Role of Ubiquitination in
Hepcidin-independent and Hepcidindependent Degradation of Ferroportin.
Cell Metab. 2011 Nov 2;14(5):635–46.
doi: 10.1016/j.cmet.2011.09.008
(hereafter referred to as ‘‘Cell Met. Nov.
2011’’) Retracted: Cell Met. 2012 Jun
6;15(6):927. doi: 10.1016/
j.cmet.2012.04.107.
• Decoupling Ferritin Synthesis from
Free Cytosolic Iron Results in Ferritin
Secretion. Cell Metab. 2011 Jan
5;13(1):57–67. doi: 10.1016/
j.cmet.2010.12.003 (hereafter referred to
as ‘‘Cell Met. Jan. 2011’’). Retracted: Cell
Met. 2012 Jun 6;15(6):927. doi: 10.1016/
j.cmet.2012.04.012.
ORI found that these acts constitute a
significant departure from accepted
practices of the relevant research
community. Specifically, ORI found by
a preponderance of the evidence that
Respondent engaged in research
VerDate Sep<11>2014
18:02 Sep 01, 2023
Jkt 259001
60695
misconduct by intentionally,
knowingly, or recklessly falsifying and/
or fabricating:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
• a western blot image in Figure 5B
(right bottom panel) of Dev. Cell 2008
by reusing and relabeling an image of
three western blot bands to represent
the results of different experiments
• western blot images in Figure 1C (top
and bottom panels) of Cell Met. Nov.
2011 by reusing and relabeling an
image of western blot bands to
represent the results of two different
experiments
• western blot images in Figures 1D and
3 of Cell Met. Nov. 2011 by reusing
and relabeling one image to represent
the results of two different
experiments
• western blot images in Figures 2Aii
and 2B of Cell Met. Nov. 2011 by
reusing and relabeling one image as
representing the results of two
different experiments
• western blot images in Figures 2Aii
and 5 of Cell Met. Nov. 2011 by
reusing and relabeling one image as
representing the results of two
different experiments
• images in Figure 4B (top and bottom
left panels) of Cell Met. Jan. 2011 by
reusing and relabeling an image of an
autoradiogram to misrepresent the
reported experimental conditions and
results
National Institutes of Health
The following administrative actions
have been implemented:
(1) For a period of three (3) years,
beginning on August 21, 2023,
Respondent is debarred from
participating in ‘‘covered transactions’’
as defined in 42 CFR 180.200 and
procurement transactions covered under
the Federal Acquisition Regulation (48
CFR chapter 1).
(2) Respondent is prohibited from
serving in any advisory capacity to PHS
including, but not limited to, service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant for a period of three (3) years,
beginning on August 21, 2023.
(3) In accordance with 42 CFR
93.407(a)(1) and 93.411(b), HHS will
send to the journal Developmental Cell
a notice of ORI’s findings and the need
for retraction or correction of Dev Cell.
2008 Jul;15(1):62–73. doi: 10.1016/
j.devcel.2008.05.014.
Dated: August 30, 2023.
Sheila Garrity,
Director, Office of Research Integrity, Office
of the Assistant Secretary for Health.
[FR Doc. 2023–19086 Filed 9–1–23; 8:45 am]
BILLING CODE 4150–31–P
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
National Institute of Dental and
Craniofacial Research; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Advisory
Dental and Craniofacial Research
Council, September 12, 2023, 4:45 p.m.
to September 13, 2023, 3:30 p.m.,
National Institutes of Health, Natcher
Building, 45 Center Drive, Bethesda, MD
20892, which was published in the
Federal Register on August 17, 2023, FR
Document 2023–17712, 88 FR 56028.
The National Advisory Dental and
Craniofacial Research Council Open and
Closed Sessions meeting room has
changed from the Natcher Building, 45
Center Drive, Bethesda, MD 20892, and
will now be held at the John Edward
Porter Neuroscience Research Center
Building, 35 Convent Drive Room 620/
630, Bethesda, MD 20892. Meeting
times remain the same. The meeting is
partially closed to the public.
Dated: August 29, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–19017 Filed 9–1–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket Number DHS–2023–0020]
Agency Information Collection
Activities: Generic Clearance for
Improving Customer Experience (OMB
Circular A–11, Section 280
Implementation), 1601–0029
Department of Homeland
Security (DHS).
ACTION: 30-Day notice and request for
comments.
AGENCY:
The Department of Homeland
Security, DHS will submit the following
information collection request (ICR) to
the Office of Management and Budget
(OMB) for review and clearance in
accordance with the Paperwork
Reduction Act. DHS previously
published this information collection
request (ICR) in the Federal Register on
June 23, 2023, for a 60-day public
comment period. No comments were
received by DHS. The purpose of this
notice is to allow additional 30-days for
public comments.
DATES: Comments are encouraged and
will be accepted until October 5, 2023.
SUMMARY:
E:\FR\FM\05SEN1.SGM
05SEN1
]]>Agencies
[Federal Register Volume 88, Number 170 (Tuesday, September 5, 2023)]
[Notices]
[Pages 60694-60695]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-19086]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made against Ivana
Frech, Ph.D. (formerly Ivana De Domenico) (Respondent), former
Assistant Professor, Department of Internal Medicine, University of
Utah (UU) School of Medicine. Respondent engaged in research misconduct
in research supported by U.S. Public Health Service (PHS) funds,
specifically National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), National Institutes of Health (NIH), grants R01
DK070947, R01 DK090257, and R01 DK030534, National Institute of General
Medical Sciences (NIGMS), NIH, grant P50 GM082545, National Institute
of Allergy and Infectious Diseases (NIAID), NIH, grant R01 AI051174,
and National Heart, Lung, and Blood Institute (NHLBI), NIH, grant R01
HL026922. The administrative actions, including debarment for a period
of three (3) years, were implemented beginning on August 21, 2023, and
are detailed below.
[[Page 60695]]
FOR FURTHER INFORMATION CONTACT: Sheila Garrity, JD, MPH, MBA,
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
240, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Ivana Frech, Ph.D. (formerly Ivana De Domenico), University of
Utah: Based on the evidence and findings of an investigation conducted
by UU, ORI's oversight review of UU's investigation, and additional
analysis conducted by ORI during its oversight review, ORI found that
Ivana Frech, Ph.D. (formerly Ivana De Domenico), former Assistant
Professor, Department of Internal Medicine, UU School of Medicine,
engaged in research misconduct under 42 CFR part 93 in research
supported by PHS funds, specifically NIDDK, NIH, grants R01 DK070947,
R01 DK090257, and R01 DK030534, NIGMS, NIH, grant P50 GM082545, NIAID,
NIH, grant R01 AI051174, and NHLBI, NIH, grant R01 HL026922.
ORI found by a preponderance of the evidence that Respondent
intentionally, knowingly, or recklessly falsified and/or fabricated
western blot and autoradiogram images related to mechanisms of cellular
iron regulation by reusing, relabeling, and manipulating images to
falsely report data in eight (8) figures included in the following
three (3) PHS-supported published papers:
Two Distinct Modes of ESCRT-III Recognition are Required
for VPS4 Functions in Lysosomal Protein Targeting and HIV-1 Budding.
Dev Cell. 2008 Jul;15(1):62-73. doi: 10.1016/j.devcel.2008.05.014
(hereafter referred to as ``Dev. Cell 2008'').
The Role of Ubiquitination in Hepcidin-independent and
Hepcidin-dependent Degradation of Ferroportin. Cell Metab. 2011 Nov
2;14(5):635-46. doi: 10.1016/j.cmet.2011.09.008 (hereafter referred to
as ``Cell Met. Nov. 2011'') Retracted: Cell Met. 2012 Jun 6;15(6):927.
doi: 10.1016/j.cmet.2012.04.107.
Decoupling Ferritin Synthesis from Free Cytosolic Iron
Results in Ferritin Secretion. Cell Metab. 2011 Jan 5;13(1):57-67. doi:
10.1016/j.cmet.2010.12.003 (hereafter referred to as ``Cell Met. Jan.
2011''). Retracted: Cell Met. 2012 Jun 6;15(6):927. doi: 10.1016/
j.cmet.2012.04.012.
ORI found that these acts constitute a significant departure from
accepted practices of the relevant research community. Specifically,
ORI found by a preponderance of the evidence that Respondent engaged in
research misconduct by intentionally, knowingly, or recklessly
falsifying and/or fabricating:
a western blot image in Figure 5B (right bottom panel) of Dev.
Cell 2008 by reusing and relabeling an image of three western blot
bands to represent the results of different experiments
western blot images in Figure 1C (top and bottom panels) of
Cell Met. Nov. 2011 by reusing and relabeling an image of western blot
bands to represent the results of two different experiments
western blot images in Figures 1D and 3 of Cell Met. Nov. 2011
by reusing and relabeling one image to represent the results of two
different experiments
western blot images in Figures 2Aii and 2B of Cell Met. Nov.
2011 by reusing and relabeling one image as representing the results of
two different experiments
western blot images in Figures 2Aii and 5 of Cell Met. Nov.
2011 by reusing and relabeling one image as representing the results of
two different experiments
images in Figure 4B (top and bottom left panels) of Cell Met.
Jan. 2011 by reusing and relabeling an image of an autoradiogram to
misrepresent the reported experimental conditions and results
The following administrative actions have been implemented:
(1) For a period of three (3) years, beginning on August 21, 2023,
Respondent is debarred from participating in ``covered transactions''
as defined in 42 CFR 180.200 and procurement transactions covered under
the Federal Acquisition Regulation (48 CFR chapter 1).
(2) Respondent is prohibited from serving in any advisory capacity
to PHS including, but not limited to, service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant for
a period of three (3) years, beginning on August 21, 2023.
(3) In accordance with 42 CFR 93.407(a)(1) and 93.411(b), HHS will
send to the journal Developmental Cell a notice of ORI's findings and
the need for retraction or correction of Dev Cell. 2008 Jul;15(1):62-
73. doi: 10.1016/j.devcel.2008.05.014.
Dated: August 30, 2023.
Sheila Garrity,
Director, Office of Research Integrity, Office of the Assistant
Secretary for Health.
[FR Doc. 2023-19086 Filed 9-1-23; 8:45 am]
BILLING CODE 4150-31-P
